Bionano announces publication demonstrating utility of ogm to assess genome integrity of crispr-edited cells as part of gene therapy development

San diego, nov. 29, 2023 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced a publication demonstrating the use of optical genome mapping (ogm) to identify structural variations (svs) introduced by crispr-cas9 gene editing of cd4+ t-cells that could potentially limit the therapeutic use of such edited cells.
BNGO Ratings Summary
BNGO Quant Ranking